Clinical Trials Logo

Lymphoblastic Leukemia, Acute clinical trials

View clinical trials related to Lymphoblastic Leukemia, Acute.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01186328 Terminated - Clinical trials for Leukemia, Lymphoblastic, Acute

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Start date: August 24, 2010
Phase: Phase 1
Study type: Interventional

An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow. The main goal of this phase I study is to find out the dose of EZN-3042 that can be safely given without serious side effects both alone and in combination with standard chemotherapy drugs during re-induction.

NCT ID: NCT01100658 Terminated - Brain Tumors Clinical Trials

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

Start date: May 2010
Phase: N/A
Study type: Interventional

While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness of methylphenidate in the treatment of children with attention deficit hyperactivity disorder (ADHD). However, the effectiveness of this medication for improving attention and behavioral functioning in children with medical illnesses or brain injury are less clear. Patients will be randomized to receive one week of Metadate CD (a controlled release form of methylphenidate, similar to Ritalin) and one week of placebo in a double-blind fashion.

NCT ID: NCT00798213 Terminated - Clinical trials for Leukemia, Myeloid, Acute

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Start date: January 2009
Phase: Phase 2
Study type: Interventional

Participants with acute myelogenous leukemia (AML) will be randomized to SCH 727965 or gemtuzumab ozogamicin. All participants with acute lymphoblastic leukemia (ALL) will receive SCH 727965. Part 1 of the study will determine the activity of SCH 727965 treatment in participants with AML and participants with ALL. Part 2 of the study will determine the activity of SCH 727965 treatment in participants with AML who experienced disease progression after standard treatment with gemtuzumab ozogamicin during Part 1.